<DOC>
	<DOCNO>NCT00636168</DOCNO>
	<brief_summary>The purpose study determine ipilimumab effective prevent delay recurrence prolongs survival complete resection high risk stage III melanoma</brief_summary>
	<brief_title>Efficacy Study Ipilimumab Versus Placebo Prevent Recurrence After Complete Resection High Risk Stage III Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Age â‰¥ 18 year Complete adequate resection Stage III melanoma histologically confirm melanoma metastatic lymph node Diseasefree Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 Randomization within 12 week surgery Prior therapy melanoma except surgery Autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>